Biopharmaceuticals

Raleigh – September 17, 2026 -- Endpoint Clinical L.P., a portfolio company of Arsenal Capital Partners, has acquired Boston-based Bluefin, a clinical supply forecasting and planning technology provider, expanding Endpoint's footprint from randomization and trial supply management (RTSM) into upstream supply chain planning.

Bluefin will keep operating independently across all RTSM platforms

Under the deal, Bluefin will continue to run as a standalone, RTSM-agnostic business, connecting with RTSM systems industry-wide rather than being folded exclusively into Endpoint's technology stack. Endpoint will provide global project management, implementation, quality and customer support resources to help sponsors deploy Bluefin's platform at scale.

Jersey City, N.J. – September 17, 2026 -- Tenon Medical, Inc. (NASDAQ: TNON) has closed a warrant inducement agreement generating $2,872,338.58 in gross proceeds from an institutional investor exercising 572,179 outstanding warrants in full.

Institutional investor exercises warrants for immediate cash proceeds

The exercising holder converted 572,179 existing warrants into common stock, delivering gross cash proceeds of $2,872,338.58 to Tenon before deducting advisor fees and other expenses.

Company issues new warrants covering 858,269 shares at $5.02 exercise price

In exchange for the immediate exercise, the investor received new unregistered warrants to purchase up to 858,269 shares of common stock, equal to 150% of the shares issued in the original exercise. The new warrants carry a $5.02 per-share exercise price, are immediately exercisable upon issuance, and expire five years from that date.

Short Hills, N.J. – September 17, 2026 -- Doceree has launched Intent Powered HCP Suite, extending its real-time clinical signal technology into Connected TV, LinkedIn and programmatic advertising, three channels the company says still rely on claims data that lags weeks behind actual prescribing decisions.

Doceree unifies three high-spend channels under one clinical signal layer

The suite, unveiled at the opening of Fierce Pharma Week 2026, adds CTV, Social and Programmatic to Doceree's existing Care Sequence and digital out-of-home (DOOH) offerings. All channels run through Daily Command, Doceree's pharma commercialization operating system, allowing a single physician-level clinical signal to trigger a CTV impression, a LinkedIn placement and a programmatic bid in sequence.

San Francisco – September 17, 2026 -- Deloitte has expanded its alliance with Salesforce to launch FastForward for Life Sciences, a preconfigured CRM accelerator that cuts implementation timelines to four to six months, twice as fast as traditional customized transformations.

Deloitte preconfigures 70-90% of the platform for mid-size life sciences firms

The offering combines Deloitte services, accelerators and a pre-configured Converge by Deloitte solution to deliver enterprise-grade CRM capability without the multi-year buildout typical of front-office transformations. It targets field engagement, health care professional engagement, territory management, sampling, medical science liaison workflows, compliance controls and customer data analytics.

NEW YORK – September 17, 2026 -- Inductive Bio has launched Indy, an AI medicinal chemistry agent that scored 89% accuracy on 84 real-program dose-response curves, versus 48% for Claude Opus 5 and 39% for GPT-5.6 Sol run at maximum effort settings.

Indy has doubled chemist productivity inside live partner drug discovery programs

Inductive Bio built Indy internally with its medicinal chemists, computational chemists and DMPK scientists, then deployed it across active partner programs before today's public launch. The company reports the tool doubled team productivity by taking over data QC, SAR analysis, generative chemistry runs, FEP calculation setup and project-update slide generation.

Shanghai – September 17, 2026 -- MoleculeMind, an AI-native bioengineering infrastructure company, has had research on its reactive atomistic modeling platform QuantaMind published in Science Advances, demonstrating Density Functional Theory (DFT)-level accuracy in simulating 10,000-atom biomolecular systems over tens-of-nanosecond timescales.

QuantaMind becomes first platform to simulate a complete enzyme reaction cycle

The study shows QuantaMind enabling AI to observe the full atomic-scale process of proton transfer, bond breaking and formation, and complete enzyme catalytic cycles. In industrial deployments, the platform has been scaled further to model reactive systems comprising hundreds of thousands of atoms.

Plymouth Meeting, Pa. – September 17, 2026 -- The National Comprehensive Cancer Network (NCCN) Oncology Research Program has awarded funding for four quality improvement projects targeting metastatic prostate cancer (mPCA) care, backed by Pfizer Global Medical Grants (GMG).

Four institutions receive two-year grants to standardize mPCA treatment protocols

The selected projects, each set for completion within two years, will run at UT Southwestern Simmons Comprehensive Cancer Center, Georgetown University, Northwestern University's Robert H. Lurie Comprehensive Cancer Center, and Moffitt Cancer Center. Changchuan (Charles) Jiang, MD, at UT Southwestern will lead a biomarker action-loop initiative within a major U.S. safety-net cancer program. Paul Leger, MD, at Georgetown will implement multilevel interventions across the Medstar Health Network under the I-CARE PCA project.

Seoul, South Korea – September 17, 2026 -- Yuyu Pharma has completed an 869-kilowatt (kW) solar installation at its Korean manufacturing facility, lifting total on-site solar capacity to approximately 1 megawatt (MW) and covering more than 30% of the plant's electricity needs.

New system adds to earlier 2020 and 2021 installations

The latest expansion builds on a 30 kW system installed in 2020 and a 96.6 kW system added in 2021. Combined, the three phases are expected to generate at least 1.2 million kilowatt-hours (kWh) annually, with a projected output of approximately 30.96 million kWh over 25 years.

San Rafael, Calif. – September 17, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has appointed Robert Plenge, M.D., Ph.D., to its Board of Directors, effective September 10, 2026.

Plenge brings nine-site global research oversight from Bristol Myers Squibb

Dr. Plenge currently serves as Executive Vice President, Chief Research Officer and Head of Research at Bristol Myers Squibb, directing scientific operations across nine research sites worldwide. He joined the company in November 2019 through its acquisition of Celgene Corp., where he had led the immunology and inflammation portfolio in research and early development.

Staten Island, N.Y. – September 17, 2026 -- Acurx Pharmaceuticals (NASDAQ: ACXP) presented new in vitro data showing its lead antibiotic ibezapolstat achieved a 5.51-log reduction against Clostridioides difficile in co-culture with vancomycin-resistant Enterococcus (VRE), significantly outperforming vancomycin (p=0.0112), the current standard of care.

The poster, presented by Dr. Eugenie Bassères of the University of Houston College of Pharmacy, was unveiled at the 9th International C. difficile Symposium in Bled, Slovenia, held September 8-10, 2026.

VRE strains showed high-level resistance to vancomycin but not to ibezapolstat

All tested VRE strains exhibited vancomycin resistance with minimum inhibitory concentrations (MIC) above 128 μg/mL. Ibezapolstat and fidaxomicin maintained equivalent, lower susceptibility thresholds of 2-16 μg/mL.